Where do we go first, and why
A fixed-fee engagement that answers the one question your launch strategy depends on. Delivered in weeks. No hourly meter. No scope creep.
You get a prioritized list of geographies with the regulatory, reimbursement, and commercial logic behind each rank, and a clear handoff into execution.
Before you stand up a launch team. Before you sign with a CRO in a second market. Before the board asks for a defensible global plan and you have eight weeks to produce one. Start here.
Book a Sequencing AssessmentThe first market decision sets every market decision that follows.
The reimbursement outcome in market one becomes the comparator for markets three through eight. The pricing precedent in Germany echoes into Japan. A NICE rejection propagates into the Gulf. Sequencing isn't a planning exercise — it's a portfolio decision with real spillover.
Most teams treat it as a series of regulatory filings to schedule. The teams that win treat it as a thesis to defend.
Board-ready output. Not a 60-page deck.
Ranked market sequence
Your top markets ordered for launch, with second-tier alternatives flagged and the trigger conditions that would move them up.
Rationale by market
For each market: regulatory pathway, reimbursement view, competitive density, evidence fit. The argument behind every rank.
Investment & timeline view
What each of the first three markets costs to launch and over what horizon. The number your CFO can model. The dates your COO can plan against.
Execution roadmap
How regulatory, reimbursement, and evidence work sequence across markets. Which Cenvia delivery modes activate where, and when.
A clear handoff. Or a clean stop.
Most Assessments lead into execution — Launch Studio for the first markets on the sequence, Market Accelerator for the next, Adoption Strategy once approvals are in hand. The Assessment is designed to hand off into that work cleanly.
But not every Assessment leads to a Cenvia engagement, and we don't structure it as if it should. Some teams take the sequence and execute internally. Some take it to a different partner. Some discover that their asset isn't ready to sequence and need to revisit clinical strategy first.
Whichever route you take, the artifacts are yours. The rationale is defensible. The next decision is informed.
We will not run an execution engagement without a sequencing decision behind it.
You're the right fit if:
- Pivotal data is on the horizon and the next 18 months will define your launch
- Your asset has more than one viable home market
- Your board expects a defensible global plan, not a US-only sketch
- You're a biotech, complex medtech, or innovative asset
- You want one fixed-fee answer, not a six-month consulting retainer
The cheapest decision you'll make in this launch cycle.
If a launch is on your eighteen-month horizon, a Sequencing Assessment is the cheapest decision you'll make. The fee is a fraction of one wasted quarter. The sequence shapes everything that follows.